JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on April 25, 2007; DOI: 10.1124/jpet.107.122044


0022-3565/07/3221-341-350$20.00
JPET 322:341-350, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.122044v1
322/1/341    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Monassier, L.
Right arrow Articles by Bousquet, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Monassier, L.
Right arrow Articles by Bousquet, P.

CARDIOVASCULAR

{sigma}2-Receptor Ligand-Mediated Inhibition of Inwardly Rectifying K+ Channels in the Heart

Laurent Monassier, Boris Manoury, Chloé Bellocq, Jacques Weissenburger, Hugues Greney, Diane Zimmermann, Jean-Daniel Ehrhardt, Patrice Jaillon, Isabelle Baró, and Pascal Bousquet

Laboratoire de Neurobiologie et de Pharmacologie Cardiovasculaire, Facultéde Médecine, Inserm, U-715, Facultéde Médecine, Strasbourg, France (L.M., H.G., D.Z., J.-D.E., P.B.); Laboratoire de Pharmacologie, Facultéde Médecine St Antoine, Paris, France (J.W., P.J.); and Inserm U-533 and Institut du Thorax, Université de Nantes, Facultéde Médecine, Nantes, France (B.M., C.B., I.B.)

The {sigma}2-receptor agonist, ifenprodil, was suggested as an inhibitor of G protein-coupled inwardly rectifying potassium channels. Nevertheless, an analysis of the role of {sigma}2 receptors in cardiac electrophysiology has never been done. This work aims i) to identify the roles of cardiac {sigma}2 receptors in the regulation of cardiac K+ channel conductances and ii) to check whether {sigma}2-receptor agonists exhibit class III antiarrhythmic properties. The {sigma}2-receptor agonists ifenprodil, threo-ifenprodil, LNP250A [threo-8-[1-(4-hydroxyphenyl)-1-hydroxy-propan-2-yl]-1-phenyl-1,3,8-triazaspiro[4,5]decane-4-one] (a derivative of ifenprodil devoid of {alpha}1-adrenergic and N-methyl-D-aspartate glutamate receptor-blocking properties), and 1,3-di(2-tolyl)guanidine were used to discriminate the effects linked to {sigma}2 receptors from those of the {sigma}1 subtype, induced by (±)-N-allylnormetazocine (SKF-10,047). The {sigma}2-receptor antagonist 3-{alpha}-tropanyl-2(pCl-phenoxy)butyrate (SM-21) was employed to characterize {sigma}2-mediated effects in patch-clamp experiments. In rabbits, all {sigma}2-receptor agonists reduced phenylephrine-induced cardiac arrhythmias. They prolonged action potential duration in rabbit Purkinje fibers and reduced human ether-a-go-go-related gene (HERG) K+ currents. (+)-SKF-10,047 was completely inactive in the last two tests. The effects of threo-ifenprodil were not antagonized by SM-21. In HERG-transfected COS-7 cells, SM-21 potentiated the ifenprodil-induced blockade of the HERG current. These data suggest that {sigma}2-receptor ligands block IKr and that this effect could explain part of the antiarrhythmic properties of this ligands family. Nevertheless, an interaction with HERG channels not involving {sigma}2 receptors seems to share this pharmacological property. This work shows for the first time that particular caution has to be taken toward ligands with affinity for {sigma}2 receptors. The repolarization prolongation and the early-afterdepolarization can be responsible for "torsades de pointe" and sudden cardiac death.


Received March 1, 2007; accepted April 24, 2007.

Address correspondence to: Laurent Monassier, Laboratoire de Neurobiologie et de Pharmacologie Cardiovasculaire, Facultéde Médecine, INSERM U-715, 11 rue Humann, 67085 Strasbourg, France. E-mail: laurent.monassier{at}medecine.u-strasbg.fr







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.